Evidence map›Paper›PMID 41179683›Full record

ArticleFrontiers in oncology2025

Acute obinutuzumab-induced thrombocytopenia in follicular lymphoma: case report and literature review.

Jieyi Zhou, Miaomiao Chen, Yi Zhang, Ce Xu, Rong Li

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jieyi ZhouDepartment of Nuclear Radiation Injury Protection and Treatment, Naval Medical Center, Naval Medical University, Shanghai, China.
Miaomiao ChenDepartment of Nuclear Radiation Injury Protection and Treatment, Naval Medical Center, Naval Medical University, Shanghai, China.
Yi ZhangDepartment of Nuclear Radiation Injury Protection and Treatment, Naval Medical Center, Naval Medical University, Shanghai, China.
Ce XuDepartment of Nuclear Radiation Injury Protection and Treatment, Naval Medical Center, Naval Medical University, Shanghai, China.
Rong LiDepartment of Nuclear Radiation Injury Protection and Treatment, Naval Medical Center, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Obinutuzumab, a type II anti-CD20 monoclonal antibody used in the treatment of follicular lymphoma, is associated with a higher incidence of adverse events, including thrombocytopenia, compared to rituximab. We report a case of severe, acute thrombocytopenia induced by obinutuzumab and explore its potential mechanism. Case presentation: A 47-year-old woman with follicular lymphoma developed recurrent, severe (grade III-IV) thrombocytopenia within 24 h following obinutuzumab administration, starting from her second treatment cycle. Subsequent bone marrow aspiration revealed significant megakaryocyte hyperplasia but with impaired platelet production. Key laboratory findings included elevated levels of pro-inflammatory cytokines TNF-α and IL-6, decreased complement levels, and reduced IgM, while the platelet antibodies tested were negative. The patient's thrombocytopenia was managed and improved with treatments including recombinant human thrombopoietin (rhTPO) and platelet transfusions. Conclusion: Obinutuzumab can rarely cause acute, severe thrombocytopenia, possibly through a combination of immune-mediated platelet destruction and impaired megakaryocyte maturation.

Indexed as

case reportfollicular lymphomahematologic malignanciesimmune mechanismobinutuzumabthrombocytopenia

Identifiers

PMID41179683
PMCPMC12575155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.